(Q38188290)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

David A. Barrett

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Pavel Gershkovich

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Dhiaa A Taha

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

25 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

164

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

85-109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

Pharmacological actions of statins: a critical appraisal in the management of cancer

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Clinically relevant differences between the statins: implications for therapeutic selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

The origin of the statins. 2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin-induced myopathy: the two faces of Janus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

The myotoxicity of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Managing the underestimated risk of statin-associated myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

7 January 2021

Drug-induced myopathies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Narrative review: statin-related myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin-induced myopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Molecular basis of statin-associated myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin-associated myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statins--a cure-all for the brain?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin-induced apoptosis and skeletal myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

The role of coenzyme Q10 in statin-associated myopathy: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Metabolism and function of coenzyme Q.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Muscle coenzyme Q: a potential test for mitochondrial activity and redox status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Lovastatin decreases coenzyme Q levels in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Lovastatin decreases coenzyme Q levels in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

The effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibition on tissue levels of carnitine and carnitine acyltransferase activity in the rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Inhibitory effects of statins on human monocarboxylate transporter 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Lactic acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter isoform MCT3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Transport mechanism for L-lactic acid in human myocytes using human prototypic embryonal rhabdomyosarcoma cell line (RD cells).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Effects of acidification and alkalinization agents on statins-induced muscle toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Preventive effects of bicarbonate on cerivastatin-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Simvastatin represses protein synthesis in the muscle-derived C₂C₁₂ cell line with a concomitant reduction in eukaryotic initiation factor 2B expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Toxicity of statins on rat skeletal muscle mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Cell sensitivity assays: the MTT assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Bicarbonate supplementation as a preventive way in statins-induced muscle damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Inhibition of Rab1 GTPase and Endoplasmic Reticulum-to-Golgi Trafficking Underlies Statin's Toxicity in Rat Skeletal Myofibers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

In situ detection of apoptosis by the TUNEL assay: an overview of techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Simvastatin induces impairment in skeletal muscle while heart is protected.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

New insights into mechanisms of statin-associated myotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Effects of HMG-CoA reductase inhibitors on excitation–contraction coupling of rat skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Rosuvastatin: characterization of induced myopathy in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Biomarkers of drug-induced skeletal muscle injury in the rat: troponin I and myoglobin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Experimental simvastatin-induced myopathy in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Association between statin-associated myopathy and skeletal muscle damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

MRI in lipid-lowering agent-associated myopathy: a retrospective review of 21 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

7 January 2021

Statin induced myopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Evidence-based management of statin myopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin myopathy: the iceberg or its tip?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Safety issues with statin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Serum creatine kinase levels and renal function measures in exertional muscle damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Electrodiagnostic evaluation of myopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin-associated myopathy with normal creatine kinase levels. Case report from a Norwegian family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Risks associated with statin therapy: a systematic overview of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Frequency of creatine kinase elevation during treatment with fluvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Elevated skeletal muscle phosphodiesters in adults using statin medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Neuromuscular rehabilitation and electrodiagnosis. 3. Diseases of muscles and neuromuscular junction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

An assessment of statin safety by muscle experts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin-associated myopathy with normal creatine kinase levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Genetic risk factors associated with lipid-lowering drug-induced myopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Inflammatory myopathy associated with statins: report of three cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Human skeletal muscle drug transporters determine local exposure and toxicity of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Impact of statin dosing intensity on transaminase and creatine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Study on the conversion of three natural statins from lactone forms to their corresponding hydroxy acid forms and their determination in Pu-Erh tea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Acute lipophilicity-dependent effect of intravascular simvastatin in the early phase of focal cerebral ischemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

DFT study on hydroxy acid-lactone interconversion of statins: the case of atorvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

DFT study on hydroxy acid–lactone interconversion of statins: the case of fluvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin safety: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Chromatography-mass spectrometry methods for the quantitation of statins in biological samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Role of P-glycoprotein in statin drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

HMG-CoA reductase inhibitors and P-glycoprotein modulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Risk factors for statin-associated rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statins: mechanism of action and effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Current overview of statin-induced myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin safety: an assessment using an administrative claims database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Meta-analysis of statin effects in women versus men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Individualising the risks of statins in men and women in England and Wales: population-based cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

CYP2D6*4 polymorphism is associated with statin-induced muscle effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Pharmacogenetics, pharmacogenomics, and individualized medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

The genetics of statin-induced myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Transporter pharmacogenetics and statin toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

SLCO1B1 variants and statin-induced myopathy--a genomewide study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

Statin and fibrate associated myopathy: study of eight patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.01.013

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRSL.2014.01.013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24530275%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference